Thousands of Ford vehicles are subject to a "Do Not Drive" order after it was discovered that they have faulty brakes.

A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficacy in a phase 1 trial.

Lilly now plans to file for approval to add the heart failure indication to the label for tirzepatide, which is already sold as Mounjaro for type 2 diabetes and Zepbound for obesity, later this year.

Heart transplantation remains the optimal long-term treatment for appropriate patients with advanced heart failure. However, the donor heart shortage is a limiting factor, and the risk profile of ...